JMP Securities Downgrades Achillion Pharmaceuticals (ACHN) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Piper Jaffray Downgrades Achillion Pharmaceuticals (ACHN) to Neutral
September 30, 2013 8:32 AM EDTPiper Jaffray downgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $7.24 yesterday, with a 52 week range of $6.12-$11.36.... More
William Blair Downgrades Achillion Pharmaceuticals (ACHN) to Market Perform
September 30, 2013 7:41 AM EDTWilliam Blair downgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Outperform to Market Perform with a price target of $5.00.
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on... More
BofA/Merrill Lynch Downgrades Achillion Pharmaceuticals (ACHN) to Underperform
September 30, 2013 6:45 AM EDTBofA/Merrill Lynch downgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Buy to Underperform.
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $7.24 yesterday, with a 52 week range of $6.12-$11.36.... More
Achillion Pharma (ACHN) Says FDA Unable to Resolve Clinical Hold on Sovaprevir, Gives Pipeline Update
September 27, 2013 4:33 PM EDTAchillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today provided an update on development of compounds in its pipeline of therapies for the treatment of chronic hepatitis C virus, or HCV. Achillion today received a response from the U. S. Food and Drug Administration, or FDA, on the clinical hold related to sovaprevir, Achillion's NS3 protease inhibitor. The FDA response indicated that, while Achillion's submission addressed all issues noted in the FDA's June 29, 2013 letter, the FDA concluded that the removal of the clinical hold is not warranted.
"While we are disappointed that we... More
Achillion Pharmaceuticals (ACHN) Halted News Pending
September 27, 2013 4:14 PM EDTAchillion Pharmaceuticals (Nasdaq: ACHN) Halted News Pending... More
